Protalix BioTherapeutics Scheduled to Report Q3 Earnings on November 10
Protalix BioTherapeutics (PLX) is set to release its third-quarter financial results on Tuesday, November 10, prior to the market opening. Market analysts have established a consensus earnings per share (EPS) estimate of -$0.02 and a revenue projection of $12.31 million, which represents a significant year-over-year decline of approximately 30.3%. The upcoming report follows a period of volatility for the company, including a previous quarter where GAAP EPS beat expectations at $0.05. Investors are closely monitoring the company's commercial progress, particularly regarding its product Elfabrio and its long-term market share targets in the Fabry disease sector.
Topics: earnings_announcement eps_beat financial_results revenue_beat